PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1840454

Lp(a) interactions.

W J McConathy·V N Trieu
View original source ↗Export metadata ↓

Abstract

In this report, we have summarized our recent studies on lipoprotein(a) (Lp(a)) and its interactions with apolipoprotein B-containing lipoproteins (ApoB-Lp). These findings implicate the kringle-4-like domains of Apo(a) in the binding of Lp(a) to other ApoB-Lp and point to proline as important in this interaction. Other studies have indicated that Lp(a) interacts with the subendothelial extracellular matrix (ECM) and that Lp(a) is inversely related to plasma triglycerides. Since Apo(a) also has an affinity for ApoB-Lp, enhanced binding of Apo(a) to the arterial wall could increase the accumulation of LDL in the matrix and thus promote the development of cardiovascular disease.

Explore related subjects

Apolipoproteins AApolipoproteins BBinding, CompetitiveExtracellular MatrixHumansLigandsLipoprotein(a)LipoproteinsPlasminogenProlineTriglyceridesJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W J McConathy, V N Trieu. 1991. Lp(a) interactions.. https://doi.org/10.1016/0163-7827(91)90016-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.

STUDY OBJECTIVE: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17 beta-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycle. DESIGN: Open longitudinal prospective study. DURATION: Twelve 28 days treatment cycles. SETTING: Gynaecological department of university hospital. SUBJECTS: 27 healthy postmenopausal women. RESULTS: After treatment for six cycles serum concentrations of FSH and LH decreased significantly with 43.0% and 24.4%, respectively. Serum concentrations of 17 beta-oestradiol and oestrone increased significantly with 302% and 792%, respectively, and SHBG increased as well with 111% (P < 0.01). Serum total cholesterol decreased with 9.0% (P < 0.01). Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased with 16.3% (P < 0.01) and HDL-cholesterol increased with 8.0% (P < 0.01). This was accompanied with similar significant changes in the apolipoproteins: apolipoprotein A-I rose with 14.4% and apolipoprotein B decreased with 6.0%. Serum triglycerides and VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. Lipoprotein (a) decreased with 17.5% (P < 0.01). These results more or less sustained at cycle 12 of treatment. Serum concentrations of antithrombin III and glucose did not change. Fibrinogen decreased slightly but significantly below the initial value. CONCLUSIONS: This combination replacement therapy gives beneficial changes in lipid-metabolism, indicating a reduced risk of developing coronary heart disease without unfavourably changing coagulation and glucose metabolism. The expected beneficial changes with oestradiol alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this oestrogen/progestagen scheme can, indeed, be recommended for use in HRT.

Apolipoproteins A↗